Allergic reactions to stinging Hymenoptera have been recognized for millennia. Epidemiological data show that 0.15% to 7.5% of the general population report an allergic reaction to Hymenoptera stings (1-3). Allergic reactions to hymenoptera venoms can be life-threatening or cause significant morbidity. About 40 fatalities per year are reported in the United States but post-mortem studies highlight both increased tryptase levels and specific IgE in the serum of subjects who experienced unexplained deaths (4) (5) (6) , especially in summertime.
Reactions to Hymenoptera stings are classified into normal or large local reactions, systemic anaphylactic reactions, systemic toxic reactions and unusual reactions (7) . Systemic anaphylactic reactions are most often IgE-mediated. The skin, the gastrointestinal, respiratory and cardiovascular systems can be involved. The degree of the severity of the systemic reactions is classified in 4 grades according to Miiller (8) (Table I) .
Specific subcutaneous immunotherapy (SCIT) is very effective in Hymenoptera sting allergic patients. It is administered by subcutaneous injections of progressively increasing doses of pure venom extract until reaching a maintenance dose of 100 ug per month (4) .
Many regimens for initial specific SCIT have been reported. Two standard regimens aim to achieve the 100 ug dose in either 8 or 15 weeks (4) . The time required to reach the maintenance dose with rush and ultra-rush protocols may vary from days to hours, respectively (9) (10) (11) (12) Venom SCIT may be complicated by systemic reactions. Systemic reactions are more frequent in honey bee venom immunotherapy than Vespula venom (\3). In a recent EAACI-multicenter study 20% ofpatients had systemic reactions corresponding to 1.9% of injections during the dose-increase phase and 0.5% during the maintenance phase (14) . Rush protocols seem to be as safe as slower protocols (11) (12) 15) .
Sublingual immunotherapy (SLIT) is currently accepted for the treatment of allergic respiratory diseases. Double-blind, placebo-controlled studies have shown the efficacy and the safety of SLIT both in allergic rhinoconjunctivitis and asthma (16) (17) (18) (19) (20) . Ultra-rush regimens of SLIT induction have been carried out with good safety and efficacy profiles (21) (22) .
The immunologic mechanisms underlying SLIT in respiratory allergy are still unclear, but a recent study shows that SLIT induces regulatory T-cell (T reg) suppression through IL-IO during the early phase and specific non-reactivity and immune deviation of allergen-specific T-cells during the later phase oftherapy (23) . There is no unanimous consent regarding the role of modifications of specific IgE and IgG4 when considering the mechanism of action of SLIT.
SLIT would be a useful candidate therapy for Hymenoptera venom allergy because of its safety profile, but in Literature there is just one report regarding patients with large local reactions caused by honeybee stings (24) . No data are available regarding patients with systemic reactions to Hymenoptera stings.
The aim of this study is to assess tolerability, safety and efficacy of ultra-rush SLIT with wasp venom compared to ultra-rush SCIT.
MATERIALS AND METHODS

Study design
This is an open prospective pilot case-control study to evaluate the tolerability, safety and efficacy of an ultra-rush SLIT with Vespula venom vs. ultra-rush subcutaneous immunotherapy (SCIT).
A written informed consent was obtained from all our patients and the study was approved by our local ethics committee.
We analyzed the data of 41 wasp venom allergic patients who were treated with sublingual (SLIT group) or subcutaneous (SCIT group) ultrarush immunotherapy with Vespula venom in the Allergy Department of Catholic University of Rome from January 2005 to December 2007. They all had a clinical history of systemic reactions to wasp stings and positive allergy testing. The exclusion criteria were: pregnancy; use of -blockers; cardiovascular, renal or respiratory diseases. Before starting the desensitization protocol, the clinical history was taken by the investigator and the reaction was classified according to MUlier (8) . Patients underwent a full allergological evaluation.
Skin tests
Skin prick and, if negative, intradermal tests with purified Hymenoptera venom extracts (Phannalgen, ALK-AbeIl6, Milan, Itlay) were performed in all patients at increasing concentrations of 0.0 I, O. I and I ug/rnl, according to the recommendations of the EAACI Interest Group on Insect Venom Hypersensitivity (7) . Reactions at least 3 mm > than controls in diameter for prick tests or 5 mm > for intradermal tests were considered positive. Histamine (at a concentration of 10 mg/ml) as positive control and saline as negative control were used. Skin tests were performed before starting the desensitization protocol, and after 6, 12 and 24 months of specific immunotherapy.
In vitro tests
Specific IgE and IgG4 to wasp venom were detected in all patients (UniCAP, Pharmacia, Uppsala, Sweden) before starting the desensitization protocol, and after 6, 12 and 24 months of specific immunotherapy. Values of 0.35 kU/L or greater were considered as positive for specific IgE while the cut-off for specific IgG4 was of 0.15 mg/L. Blood samples were obtained at evaluation and sera were stored at -20 0 C until assayed.
Ultrarush desensitisation protocol SLIT group
After the diagnosis of IgE-mediated hypersensitivity to wasp venom, 21 patients, who refused the SCIT treatment for non-medical reasons, underwent the sublingual rush desensitisation protocol according to the EAACI recommendations for subcutaneous venom immunotherapy (13) . Blood pressure, pulse rate and peak espiratory flow were measured before starting the protocol. An aqueous wasp venom extract (Aquagen, ALK-Abe1l6) was used for the ultrarush sublingual desensitisation protocol (Table l) . Each dose was administered every 20 minutes and patients were monitored during and for 3 hours after the end of the protocol till the final dose of 30 drops of the extract containing 100,000 SQ-U/mL. The drops of venom extract were put under the patients' tongues and then swallowed after almost I minute. The maintenance dose was of 10 drops of pure venom extract 3 times a week, for a total dose of 100,000 SQ-U weekly.
The ultrarush protocol was performed in a day hospital regimen, without hospitalization.
SCITgroup
The SCIT group was formed by 20 patients who were treated with subcutaneous ultrarush immunotherapy with Vespula venom extract (Pharmalgen, Alk-Abello). Patients received IOU ug of Vespula venom as indicated in Table II (II). The maintenance dose was of 100 ug of venom monthly.
Statistical analysis
For all statistical analysis the statistical package SPSS program version 13 was used. For descriptive statistics we report the mean, median and standard deviation with 95% confidence intervals (Cl) ofthe mean and percentage distribution. The ANOVA with Dunnett post test and 3x2 Chi-square tests were used to evaluate immunological changes over time and to compare distribution of reactions after field-stings between cases and controls. The absolute P values are shown, <0.05 being taken as significant.
RESULTS
SLIT group
Twenty-one patients, 6 females and 15 males, aged from 14 to 71 years (mean 38 ± 16) were included in the SLIT group protocol. Clinical characteristics of patients are described in Table IV . During the ultrarush sublingual protocol 2 patients out of 21 (9.5%) experienced mild side-effects: one patient had dysphagia after the 4 th dose (1 drop of venom extract diluted 1:10), with spontaneous remission, and the other had generalized itching which remitted after an oral antihistamine. No other side-effects were detected. Two patients stopped the treatment after the ultrarush phase because of lack of compliance while other two patients continued the maintenance phase of the treatment but did not Table I . Classification ofsystemic reactions to insect stings (8) .
Grade I Generalized urticaria, itching, malaise and anxiety Grade II Any of the above plus two or more of the following: angioedema, chest constriction, nausea, vomiting, diarrhea, abdominal pain, dizziness Grade III Any of the above plus two or more of the following: dyspnea, wheezing, stridor, dysarthria, hoarseness, weakness, confusion, feeling of impending disaster Grade IV Any of the above plus two or more of the following: fall in blood pressure, collapse, loss of consciousness, incontinence, cyanosis undergo further evaluation as previously described. Nine patients have been treated for 24 months, 1 for 12 months and the remaining 7 for six months and they are all still being treated. Specific IgE and specific IgG to wasp venom did not show any significant modification after 6, 12 and 24 months (ANOVA test: P=0.68 and P=0.9, respectively) ( Figs. 1 and 2) .
Four patients were field-stung by a wasp during the treatment. Two patients did not experience any reaction: one of them, with a clinical history of a grade III reaction, was re-stung twice after 14 and 24 months, and the other, with a clinical history of a grade IV reaction was stung after 1 year. A third patient, with a clinical history of a grade II reaction, who was re-stung after 1 month showed a large local reaction only that did not require any treatment. The last one, with a clinical history of a grade III reaction, was re-stung twice: after 12 months he had throat constriction and a large local reaction and was treated with intramuscular corticosteroids and antihistamines; after 24 months he was stung again and had throat constriction: symptoms promptly receded after self-administration of intramuscular corticosteroids. However, it is relevant that SLITtreated patients after field insect stings had no fatal reactions or anaphylaxis.
SCITgrolip
Twenty patients, 16 males and 4 males, aged from 17 to 60 years (mean 35 ± 14) underwent subcutaneous ultra-rush immunotherapy. Clinical characteristics of the patients are described in Table  IV .
During the ultra-rush phase 3 patients out of 20 (15%) experienced some side-effects: 2 showed a large local reaction that required medical treatment (intramuscular corticosteroids and antihistamines and topical corticosteroids and oral antihistamines, respectively) and 1 had headache and stomach ache, that did not require any treatment. No differences (P=0.8) were observed in treatment-related side effects in comparison with SLIT-treated patients. Specific IgE showed a significant (P=O.OO 1; ANOVA Dunnett test) increase after 6 months of treatment and then returned to baseline levels while specific IgG 4 showed a significant increase (ANOVA test: p=O.O 1) at 6, 12 and 24 months in comparison with baseline (Dunnett test) ( Figs. 1 and 2) . Nine patients were field-stung during the treatment: 8 of them experienced a large local reaction and in 4 cases they were treated with oral antihistamines or intramuscular corticosteroids. A systemic reaction was observed in one patient who experienced dizziness and was treated with intramuscular betamethasone.
DISCUSSION
Specific venom immunotherapy is indicated in children and adults with a positive history of severe systemic reactions and documented sensitization to the culprit insect with either skin tests and/or detection of serum specific IgE (13) . When deciding whether to start venom immunotherapy, the physician should take into account also other risk factors (such as occupations and/or hobbies where the risk of exposure is high, the culprit insect itself, psychological factors, concomitant diseases etc.) (13) .
The first immunotherapy with pure venom extract was carried out in 1974 and protocols of various duration have been devised to maximize protection, minimize side-effects and optimize patient convenience (25) .
Subcutaneous venom immunotherapy can be complicated by systemic reactions. Bee venom immunotherapy is at higher risk of systemic reactions than Vespula venom, probably because of the differences in the quality of the extracts (26) .
Reports in the literature highlight a high variation (0-46%) in the incidence of side effects attributable to venom immunotherapy (13) . In a recent EAACImulticenter study, 20% of patients had systemic reactions corresponding to 1.9% of injections during the dose-increase phase and 0.5% during the maintenance phase. The vast majority of these reactions were mild: only one-third required medical treatment. Injected or inhaled adrenaline was used in 6 patients. Female sex, bee-venom extract and rapid dose increase are the main risk factors (14) . However, some other studies using rush protocols have suggested to be as safe as slower ones (11-12, 27-28).
Sublingual immunotherapy has been shown to be as effective as subcutaneous immunotherapy, but with lower side-effects, for the treatment of respiratory allergy (29) . Moreover, sublingual immunotherapy can be carried out at home by the patient himself without medical supervision. Venom subcutaneous immunotherapy should be carried out only in high specialized centres by fully trained medical personnel with expertise in this field. SLIT can be performed by the patient himself and it is less traumatic than SCIT. For these reasons we decided to attempt a sublingual desensitizing treatment with an aqueous extract in patients with wasp venom allergy. SLIT significantly reduced the extent of large local reactions in honeybee venom allergic patients, as already demonstrated by other authors (24) .
The ultra-rush phase was well tolerated and only one patient needed oral antihistamines and could continue the treatment. No side-effects were reported during the maintenance dose.
As regards the efficacy of the treatment, we would like to underline that four patients were field-stung (two patients were stung twice) during the treatment. Only one of them experienced mild systemic reaction. Systemic reactions after field stings are described also in patients undergoing SCIT: some authors report a reaction rate to yellow jacket sting of 10.9% (30) .
Our pilot study suggests that when compared to venom SCIT, SLIT appears to have a similar safety and efficacy profile. However, in comparison to SCIT treated patients, in SLIT group we did not observe significant immunological modifications. In the SCIT group specific IgG4 serum levels increased significantly. Regarding specific IgE, a significant increase was observed after 6 months; values returned to baseline levels after 24 months. Similar findings were observed also by other authors (12, 27) . Specific IgG4 have been considered as protective blocking antibodies and it seems that they are involved in the mechanism of action of SLIT for honeybee venom (24) .
Whether SLIT is able or not to modify the immunological response is still matter of debate: in fact, some papers did not show any modifications of specific IgG4 during sublingual immunotherapy with pollen allergens, with house dust mites and with latex, even in pediatric patients (31) (32) (33) (34) (35) . On the contrary, other works underlined the capability of SLIT with pollen allergens or with house dust mites to induce an increase of specific IgG4 (36) (37) (38) (39) . Despite the lack of unanimous consent regarding the mechanism of action of SLIT, several trials have shown the efficacy of SLIT in improving symptoms in patients with allergic rhinitis and/or bronchial asthma, and with latex allergy.
The mechanism of action of SLIT for respiratory allergy has not to date been fully described:
during SLIT, the allergen is captured locally by Langerhans-like dendritic cells (DC) (40); Des then mature and migrate to proximal draining lymph nodes. Oral Langerhans-like cells produce IL-lO, TGF-~and upregulate indoleamine 2-dioxygenase, a rate-limiting enzyme metabolizing tryptophan, thereby resulting in a decrease in T-cell proliferation. However, even if there is no evidence of T reg cell induction by sublingual route, there is preliminary data showing that SLIT elicits IL-IO-producing T cells in humans (41) .
It is well established that SLIT requires more allergen than SCIT to reach the same level ofefficacy. For this reason we chose a maintenance regimen of 100,000 SQ-U weekly, which is 4 times higher than SCIT. Because of the higher dose of the maintenance regimen, SLIT is more expensive than SCIT.
In conclusion, this was a case-control study with the aim of testing the possibility to perform SLIT in patients with wasp venom allergy. Our preliminary results, even if carried out in small number of patients, show that wasp venom SLIT, when compared to SCIT, shows a similar safety profile treatment. SLIT efficacy has not been confirmed by insect sting challenges, but our preliminary results seem to be promising. However, larger, randomised controlled studies are needed to assess efficacy of Hymenoptera venom SLIT and pharmacokinetic data regarding the sublingually-administered venom are necessary.
